When: October 2025
Where: Online – see recording link below
Douglas CDMO recently featured in Outsourced Pharma’s Capacity Update Week, a premier digital showcase of global manufacturing leadership. As drug molecules increase in complexity, choosing a partner with proven capacity and technical expertise is critical for clinical and commercial success.
In this interactive session, Douglas CDMO – a fully integrated New Zealand-based CDMO – details our end-to-end drug development pathway. We specialize in the formulation and commercial manufacturing of high-potency active pharmaceutical ingredients (HPAPIs), specifically focusing on small molecule softgels and liquid dosage forms.
Learn how our team addresses the industry’s toughest formulation challenges, including:
- Bioavailability enhancement: Utilizing softgel technology to optimize the delivery of poorly soluble compounds.
- High-containment manufacturing: Safely handling highly potent small molecules for oncology and specialty therapeutics.
- Therapeutic Expertise: Proven track record in developing prescription medicines for dermatology, oncology, endocrinology, and the central nervous system (CNS).
- Scalable solutions: From initial R&D in our new $50M innovation hub to large-scale commercial supply.
Featured Speakers: Lora Wallis (Head of Delivery) and Chris Cuthbertson (Program Manager) share unique insights into how our flexible, partnership-driven approach accelerates your speed-to-market.
Lora Wallis, Head of Delivery – Pharma
Other posts you may be interested in...
Articles
Bespoke client solutions: A personalized approach as a privately owned CDMO
Douglas CDMO is making its mark in the pharmaceutical development industry with their flexible and personalized approaches to client needs.
Learn MoreArticles
Smart softgels: driving innovation in pharma
In the dynamic landscape of pharmaceuticals, one innovation has consistently pushed the boundaries of drug delivery: the softgel capsule.
Learn MoreCase Studies
Seizing market share pre-patent expiry: Navigating a paragraph IV ANDA submission
Douglas CDMO partnered with a US pharmaceutical firm to develop a cutting-edge generic isotretinoin softgel, overcoming regulatory and technical complexities, launching with remarkable success.
Learn More